Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2364-1746
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study ; day:1 ; month:4 ; year:2019 ; pages:1-12
Pulmonary therapy ; (1.4.2019), 1-12
- Urheber
-
Hahn, Beth
Stanford, Richard H.
Goolsby Hunter, Alyssa
Essoi, Breanna
White, John
Ray, Riju
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s41030-019-0091-0
- URN
-
urn:nbn:de:101:1-2019042201215738384067
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hahn, Beth
- Stanford, Richard H.
- Goolsby Hunter, Alyssa
- Essoi, Breanna
- White, John
- Ray, Riju
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
Therapeutic effect of long-acting muscarinic antagonist for treating uncontrolled asthma assessed using impulse oscillometry
A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town
Muscarinic receptors
Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting
Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
Therapeutic effect of long-acting muscarinic antagonist for treating uncontrolled asthma assessed using impulse oscillometry
A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town
Muscarinic receptors
Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting
Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
Therapeutic effect of long-acting muscarinic antagonist for treating uncontrolled asthma assessed using impulse oscillometry
A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town
Muscarinic receptors
Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting
Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023